Cagrilintide + GLP-1 2.5mg/2.5mg-5MG
About Cagrilintide + GLP-1 2.5mg/2.5mg-5MG
This research blend combines two distinct metabolic peptides in a single vial: cagrilintide, a synthetic long-acting amylin analog that agonizes amylin (AMY1-3) and calcitonin receptors, and GLP-1, the native incretin peptide that agonizes the glucagon-like peptide-1 receptor (GLP-1R). Because it is a physical mixture of two molecules, the blend has no single molecular formula, weight, or CAS number; each component retains its own identity, and the relevant specifications are listed per component below.
In preclinical research, the pairing of an amylin analog with a GLP-1 receptor agonist has been of interest for studying complementary signaling across the amylin and incretin axes in models of energy balance, food intake, and glucose handling. This co-formulation mirrors the scientific rationale behind combination amylin/GLP-1 research programs. This material is supplied strictly for Research Use Only and is not for human or animal use.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Handling and Storage Tips:
Keep peptides cold and away from light once received.
For short-term use (days to weeks), refrigeration at 4°C (39°F) is acceptable.
Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.
FDA Disclosure & Intended Use:
FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.
Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.
Specifications
- MaterialCagrilintide + GLP-1 2.5mg/2.5mg-5MG
- Also searched asAM833
- Research AreaMetabolic Research
- Presentation—
- TypeTwo-component peptide blend (amylin analog + incretin)
- Receptor / TargetAmylin / calcitonin receptors (cagrilintide) and GLP-1R (GLP-1)
- Purity (HPLC)≥99%
- Identity (MS)Confirmed to specification
- TestingAccredited (ISO 17025) third-party laboratory
- DocumentationPer-batch COA →
Preclinical research on combined amylin-analog and GLP-1 receptor agonist administration has explored whether the two mechanisms produce complementary effects on satiety, food intake, and metabolic parameters relative to either agent alone. Findings are specific to the experimental models used and to the individual pharmacology of each component.
These observations derive from experimental and preclinical settings and are provided for scientific context only. No human efficacy, dosing, or therapeutic conclusions are implied by this listing.
The scientific rationale for pairing an amylin analog with a GLP-1 agonist grew out of parallel development of long-acting amylin analogs such as cagrilintide and the established GLP-1 incretin field, exemplified by combination programs studying amylin plus GLP-1 receptor agonism for metabolic research.
- Kruse T, et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry.
- Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet.
- Mojsov S, Weir GC, Habener JF (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation.
Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
Are these research materials third-party tested?
Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.
What purity are the materials?
Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.
Do you provide a Certificate of Analysis (COA)?
Yes. Per-batch COA documentation is provided and is traceable by lot number.
Where do you ship from?
Materials are shipped from the USA in discreet, protective packaging.
Are these products for human use?
No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.
More Metabolic Research materials
✓ ≥99% View COA ›
MOTS-c 10MG Research Vial - Mitochondrial-Derived Peptide | Third-Party Tested
✓ ≥99% View COA ›
GLP-3 (Retatrutide) 15MG Research Vial - GLP-1/GIP/Glucagon Triple Receptor Agonist | Third-Party Tested
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · 21+
